Effect of two common GVHD prophylaxis regimens on the gut microbiome in a randomized phase 3 trial
In a prespecified companion study (BMT CTN 1801) of the randomized phase 3 BMT CTN 1703 trial comparing two common GVHD prophylaxis regimens, microbiome diversity at engraftment did not associate with non-relapse mortality, but secondary analyses found baseline microbiome diversity was associated with clinical outcomes.